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Frequent Founder Synonymous Mutation and
Unconventional Intronic Mutations
Matthieu Lacroix1, Laetitia Lacaze-Buzy1, Laetitia Furio2,3, Elodie Tron4, Manthoula Valari5,
Gerda Van der Wier6, Christine Bodemer7, Anette Bygum8, Anne-Claire Bursztejn9, George Gaitanis10,
Mauro Paradisi11, Alexander Stratigos12, Lisa Weibel13, Ce´line Deraison1 and Alain Hovnanian2,3,4,7
Netherton syndrome (NS) is a severe skin disease caused by loss-of-function mutations in SPINK5 (serine
protease inhibitor Kazal-type 5) encoding the serine protease inhibitor LEKTI (lympho-epithelial Kazal type-
related inhibitor). Here, we disclose new SPINK5 defects in 12 patients, who presented a clinical triad suggestive
of NS with variations in inter- and intra-familial disease expression. We identified a new and frequent
synonymous mutation c.891C4T (p.Cys297Cys) in exon 11 of the 12 NS patients. This mutation disrupts an
exonic splicing enhancer sequence and causes out-of-frame skipping of exon 11. Haplotype analysis indicates
that this mutation is a founder mutation in Greece. Two other new deep intronic mutations, c.283-12T4A
in intron 4 and c.1820þ 53G4A in intron 19, induced partial intronic sequence retention. A new nonsense
c.2557C4T (p.Arg853X) mutation was also identified. All mutations led to a premature termination codon
resulting in no detectable LEKTI on skin sections. Two patients with deep intronic mutations showed
residual LEKTI fragments in cultured keratinocytes. These fragments retained some functional activity, and
could therefore, together with other determinants, contribute to modulate the disease phenotype. This new
founder mutation, the most frequent mutation described in European populations so far, and these unusual
intronic mutations, widen the clinical and molecular spectrum of NS and offer new diagnostic perspectives
for NS patients.
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INTRODUCTION
Netherton syndrome (NS, OMIM 256500) is one of the
most severe inherited skin diseases of children and young
adults (Comel, 1949; Netherton, 1958). It is a rare (1 in
200,000 newborns) autosomal-recessive genodermatosis,
which classically associates congenital scaly erythroderma,
a specific hair shaft defect (trichorrhexis invaginata, TI), and
constant atopic manifestations (Traupe, 1989; Sybert, 1997;
Ong and Harper, 2006). NS newborns often present
with extensive exfoliative erythroderma of variable intensity.
Erythroderma can persist throughout life in most severe
cases or more often evolves into the typical pattern of
ichthyosis linearis circumflexa (ILC; Comel, 1949;
Hausser and Anton-Lamprecht, 1996). Dehydration, infec-
tions, and failure to thrive are frequent complications
during the neonatal period. NS patients suffer from a
broad range of allergic manifestations including atopic
dermatitis-like lesions with elevated serum IgE levels,
urticaria, asthma, angioedema, and food allergy (Judge
et al., 1994; Van Gysel et al., 2001). Pruritus and
lichenification are common. The disease can show a
fluctuating course throughout childhood and adulthood,
contributing to misdiagnosis.
We previously identified SPINK5 (serine protease inhi-
bitor Kazal-type 5) as the defective gene in NS, encoding
the serine protease inhibitor LEKTI (lympho-epithelial
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Kazal-type-related inhibitor), which is a secreted multi-
domain inhibitor, expressed in the granular layer of the
epidermis and in the inner root sheets of hair follicles
(Chavanas et al., 2000; Bitoun et al., 2003). Proteolytic
fragments of LEKTI efficiently and specifically inhibit epider-
mal proteases such as kallikrein (KLK)5, KLK7, and KLK14
(Bitoun et al., 2003; Egelrud et al., 2005; Borgono et al., 2007;
Deraison et al., 2007; Fortugno et al., 2011). In NS, loss-of-
function mutations in SPINK5 result in unopposed protease
activity in the epidermis, leading to premature (corneo)des-
mosome cleavage, abnormal filaggrin maturation, and protei-
nase-activated receptor 2 activation (Descargues et al., 2005;
Hachem et al., 2006; Briot et al., 2009; Bonnart et al., 2010).
This induces severe skin barrier impairment, and production
of proallergic and proinflammatory molecules, which have a
key role in the development of allergic manifestations in NS
(Descargues et al., 2005; Briot et al., 2009; Renner et al.,
2009; Bonnart et al., 2010). Loss of LEKTI expression is a
diagnostic feature of NS, allowing for rapid and early
diagnosis of the disease (Bitoun et al., 2003; Ong et al., 2004).
More than 60 distinct SPINK5 loss-of-function muta-
tions have been reported (Sprecher et al., 2001; Bitoun
et al., 2002a, b; Raghunath et al., 2004; Mizuno et al.,
2005; Shimomura et al., 2005; Descargues et al., 2006;
Lin et al., 2007; Zhao et al., 2007). Here, we report signi-
ficant inter- and intra-familial variations in disease expres-
sion in NS patients with no detectable LEKTI in the
skin. We unmask new and non-classical mutations affect-
ing SPINK5 pre-mRNA splicing, which were initially not
recognized as causative mutations because of their nature
and/or position.
RESULTS
Clinical features of NS and SPINK5 mutations
We report 12 individuals with NS (in the age group of
9 months to 38 years), from 10 non-consanguineous families
(Table 1). The classical triad of congenital scaly erythro-
derma, TI, and eczematous-like rashes was seen in 41%
of the patients only (5/12). Specifically, scaly erythroderma
was absent at birth in 59% of patients (7/12), TI was observed
in 83.3% of patients (10/12), and all patients developed
red eczematous-like plaques (Figure 1). Hair abnormalities
were clinically noted in 66% (8/12) of the patients. Four
patients (1, 5, 6, and 7), who displayed TI on microscopic
examination, showed dense, thin but otherwise apparently
normal hair with no alopecia at the time of examination
(Figure 1). All patients except two (4.1 and 8) developed
ILC. Asthma was found in 50% (6/12) of the patients and
angioedema in 25% (3/12) of the patients. Food allergy was
the most frequent non-cutaneous allergic manifestation,
present in 58.3% (7/12) of the patients. High IgE levels were
detected in 66.6% (8/12) of the patients (Table 1). Additional
findings included dehydration, recurrent infections, moder-
ate-to-severe pruritus, and growth retardation (Supplementary
Table S1 online).
The clinical presentation showed differences between
patients and varied over time. Both multiplex families (NS3
and NS4) showed intra-familial variability: NS3.1 developed
extensive ILC on the trunk, whereas his brother NS3.2 had
limited skin lesions and partial alopecia (Figure 1); patient
NS4.1 displayed minor eczematous-like lesions with no
alopecia, whereas his younger brother NS4.2 had ILC and
alopecia sparing the vertex; none of them had detectable TI
(Table 1).
SPINK5 direct sequencing identified only one of the
two mutations in 10 of these NS patients (3 to 12), and
no mutation in patients 1 and 2 (Table 1). A new nonsense
c.2557C4T (p.Arg853X) mutation was identified in exon 27
in NS patient 9, and four previously described mutations
in patients 3 to 8, and 10 (Table 1). To identify the second
or both SPINK5 mutations (NS1 and NS2), we carefully
analyzed genetic variations throughout SPINK5. Patients 1
and 2 both displayed a c.891C4T (C297(TGC4TGT))
variation in exon 11, in addition to a c.1820þ53G4A
(c.IVS19þ53G4A) change in intron 19, and a c.283-
12T4A (c.IVS4-12T4A) change in intron 4, respectively.
The other NS patients of this study were subsequently tested
and all displayed the c.891C4T nucleotide change (Table 1).
The recurrent and founder c.891C4T mutation triggers
skipping of exon 11 through disruption of a SF2/ASF-binding
site in an ESE sequence
We investigated the consequences of the c.891C4T change
by reverse transcription (RT)-PCR analysis of mRNA from NS1
keratinocytes (Supplementary Figure S1A online), using
primers flanking exon 11, and showed two bands of reduced
but similar intensity, one of normal size and a second of
smaller size (Figure 2a). Sequencing of the smaller amplimer
revealed skipping of the entire exon 11 (Figure 2b), changing
the phase and leading to a premature termination codon
(TGA) in exon 12 of the mutant SPINK5 transcript (Supple-
mentary Figure S1B online). We next tested the possibility
that this mutation occurred in an exonic splicing motif
and scanned the wild-type (c.891C) and mutant (c.891T)
sequence using different web-based programs. Exonic spli-
cing enhancer (ESE) finder (Cartegni et al., 2003), automated
splice site analyses (Nalla and Rogan, 2005), and human
splicing finder (Desmet et al., 2009) software indicated that
the c.891T nucleotide indeed completely abolished a SF2/
ASF-binding motif, but also predicted the creation of several
new potential exonic splicing silencers (Figure 2c), as well as
an additional hnRNPA1-binding site at the site or surrounding
the mutation (data not shown). These findings strongly
suggest that the c.891C4T mutation affects SPINK5 mRNA
splicing through disruption of the consensus ESE sequence
and the creation of a new exonic splicing silencer.
Among the 10 families carrying the c.891C4T mutation,
5 were of Greek origin and the others, except for NS1 (The
Netherlands), were also from Mediterranean background.
Haplotype analysis using seven SPINK5 microsatellite mark-
ers revealed that mutation c.891C4T segregated with the
same combination of alleles in all Greek families, and also in
the families originating from France (NS3), Kosovo (NS7
and NS8), and Southern Italy (NS9), suggesting a founder
effect in the Greek families and raising the possibility of
distant Mediterranean ancestors in these families (Figure 2d).
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c.283-12T4A and c.1820þ 53G4A mutations cause partial
intronic retention in SPINK5 transcripts
We first studied NS2 who is a compound heterozygote
for mutations c.283-12T4A in intron 4 and c.891C4T in
exon 11 (Supplementary Figure S1C online). RT-PCR analysis,
using FAM-labeled primers surrounding intron 4, showed a
400-bp amplimer corresponding to the normal SPINK5 band
in NHK, whereas a larger additional species was present in
lower amounts in NSK2 (Figure 2e). Sequence analysis of this
larger amplimer identified transcripts carrying the inclusion
of the last 10 nucleotides of intron 4 (Figure 2f), showing
that c.283-12T4A impairs SPINK5 pre-mRNA splicing
and leads to the retention of an intronic sequence (Supple-
mentary Figure S1D online). In a similar manner, NS1, who is
a compound heterozygote for c.1820þ53G4A mutation in
intron 19 and c.891C4T in exon 11, showed on RT-PCR
analysis a wild-type band and a larger SPINK5 transcript of
reduced intensity (Figure 2g). Sequencing of the larger band
showed retention of the first 54 nucleotides of intron 19
(Figure 2h), confirming that c.1820þ53G4A mutation alters
Table 1. Clinical features and SPINK5 mutations identified in the 12 NS patients in this report
Family
Age
(years)1 Sex SE Diagnostic parameters
LEKTI
detection SPINK5 mutations
2
ILC TI
Atopic
manifestations
Geographic
origin Mutation
Nucleotide
change Consequence Location Reference
1 38 F  + + E, AO, H-IgE,
U, A
Negative The
Netherlands
c.1820+53G4A* catcgg4catcag Intronic sequence
retention
Intron 19 Present study
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
2 16mo M + + + E, H-IgE, He Negative Greece c.283-12T4A* atcatg4atcaag Intronic sequence
retention
Intron 4 Present study
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
3.1 10 M  + + E, FA, AO,
H-IgE, A
Negative France p.Arg371X c.1111C4T Nonsense (PTC) Exon 13 Bitoun et al.
(2002a, b)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
3.2 2 M  + + E, FA, A Negative France p.Arg371X c.1111C4T Nonsense (PTC) Exon 13 Bitoun et al.
(2002a, b)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
4.1 5 M    E, FA, H-IgE Negative Greece p.Ala80GlyfsX18 c.238dup1 Frameshift
(PTC+18 aa)
Exon 4 Chavanas et al.
(2000)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
4.2 9mo M  + tn E, FA, H-IgE Negative Greece p.Ala80GlyfsX18 c.238dup1 Frameshift
(PTC+18 aa)
Exon 4 Chavanas et al.
(2000)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
5 2 F  + + E, FA Negative Greece c.410+1G4A TGCgt4TGCat Altered splicing Intron 5 Renner et al.
(2009)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
6 25 M + + + E, H-IgE, A Negative Greece ND Present study
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
7 26 M  + + E Negative Kosovo p.Phe51PhefsX6 c.153del1 Frameshift
(PTC+6 aa)
Exon 3 Chavanas et al.
(2000)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
8 10mo M +  + E, FA, H-IgE, He Negative Kosovo p.Phe51PhefsX6 c.153del1 Frameshift
(PTC+6 aa)
Exon 3 Chavanas et al.
(2000)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
9 13 M + + + E, H-IgE, He, A ND Italy p.Arg853X* c.2557C4T Nonsense (PTC) Exon 27 Present study
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
10 12 M + + + E, FA, AO,
H-IgE, U, A
ND Greece p.Ala80GlyfsX18 c.238dup1 Frameshift
(PTC+18 aa)
Exon 4 Chavanas et al.
(2000)
p.Cys297Cys* c.891C4T Exon skipping Exon 11 Present study
Abbrevations: A, asthma; AO, angioedema; E, eczematous-like rashes; cDNA, complementary DNA; F, female; FA, food allergy; H-IgE, hyper IgE;
He, hypereosinophilia; ILC, ichthyosis linearis circumflexa; M, male; ND, not determined; NS, Netherton syndrome; PTC, premature termination codon;
SE, scaly erythroderma at birth; TI, trichorrhexis invaginata; tn, trichorrhexis nodosa; U, urticaria.
1The age, expressed in years or in months (mo), corresponds to the patient’s age when referred to our center.
2Amino acid and nucleotide numbering refers to the cDNA sequence, with nucleotide position 1 assigned to the first nucleotide of the ATG initiation codon in
exon 1. Bases in exons are noted by upper-case letters and bases in introns by lower-case letters. The Cys297Cys mutation shared by all patients in this study is
indicated in bold. (PTC + n aa) indicates that a PTC is created n amino acids downstream of the mutation. Asterisks (*) refer to new SPINK5 mutations.
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correct SPINK5 pre-mRNA splicing (Supplementary Figure
S1F online).
NS patients 1 and 2 exhibit residual LEKTI expression in
cultured keratinocytes
As normally spliced SPINK5 transcripts were also detected
in NS1 and NS2 cultured keratinocytes, we investigated
the consequences of these new splicing events on LEKTI
production. We first confirmed that LEKTI immunostaining
was negative on skin cross-sections in NS1 and NS2 com-
pared with healthy control skin (Figure 3a). We next
performed western blotting on the supernatant of keratino-
cytes using LEKTI antibodies raised against N terminus
(D1–D6) or C terminus domains (D13–D15) of the protein.
An NS patient homozygous for the c.2471_2475delAAGA-
GinsT SPINK5 mutation, leading to a premature termination
codon without impairing splicing (Goujon et al., 2010),
showed complete absence of LEKTI (Figure 3b). In contrast,
NSK1 and NSK2 displayed weak expression of LEKTI
fragments compared with NHK (Figure 3b). In situ zymo-
graphy using casein conjugated to FITC as a substrate showed
that NS1 and NS2 had an increased proteolytic activity
compared with normal epidermis, but to a lesser extent than
in the skin of a LEKTI-null NS patient (Figure 3c). Analysis by
quantitative RT-PCR of the expression levels of downstream
targets of the KLK5–proteinase-activated receptor 2 pathway
revealed that TSLP, TNF-a, and IL-8 induction in NSK1 and
NSK2 was significantly reduced as compared with NSK
(Figure 3d). Taken together, these results provide evidence
that NS1 and NS2 patients produce residual levels of LEKTI
domains that retain functional activities, although no LEKTI is
detectable on skin sections.
NS1 NS2
NS3-1 NS3-2
NS7NS7NS5
NS8
4.5 mo
NS8
5.5 mo
NS8
10 mo
NS8
16 mo NS8
Figure 1. Clinical variability in patients with Netherton syndrome. NS1 presented with thin and dense hair despite the presence of TI. NS2 had marked
scaly erythroderma at birth, which quickly evolved into a moderate diffuse eczematous-like eruption. NS3.1 had spiky hair, red cheeks, and extensive ichthyosis
linearis circumflexa (ILC) on his chest. NS3.2, his younger affected brother, had partial alopecia and only a few eczematous-like plaques. NS5 had long,
thin, slow-growing and brittle hair with TI, eczematous-like lesions of her cheeks, and developed ILC on her trunk and on her cheeks. NS7 had dense,
normal-looking hair with TI. He developed extensive and very inflammatory lesions of ILC, made of confluent plaques prominent on the trunk and the thighs,
with scaly, double-edged and crusty lesions. NS8 presented with neonatal exfoliative erythroderma, which evolved into sharply delineated and extensive
red plaques on the entire body at 4.5 and 5.5 months (mo). Seborrheic dermatitis-like lesions of the scalp were noted at 10 months and resolved at 16 months.
His hair was thin, sparse, and long, with TI present on dermoscopy. He developed inflammatory, urticaria-like annular plaques of the thighs with no definite ILC.
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Figure 2. Consequences of c.891C4T, c.283-12T4A, and c.1820þ 53G4A mutations on SPINK5 pre-mRNA splicing. (a) Reverse transcription (RT)-PCR
analysis of mRNA from control and NS1 keratinocytes (NHK and NSK1, respectively). (b) Sequence analysis of RT-PCR amplimers from NSK1. (c) Analysis
of wild-type (WT; c.891C) and mutant (c.891T) SPINK5 intron 10–exon 11 junction with exonic splicing enhancer finder website (Cartegni et al., 2003). Note that
T is shown instead of U for consistency with the designation of the mutation. (d) Haplotype analysis of families NS2 to NS10. The SPINK5 haplotype carrying the
c.891C4T mutation is shaded in gray. (e and g) RT-PCR analysis performed on total RNA from NS2 (NSK2) and NS1 (NSK1) keratinocytes, separated by capillary
electrophoresis for c.283-12T4A, and by agarose gel for c.1820þ 53G4A mutation. (f and h) Sequence analysis of SPINK5 mutant transcripts in NS2 and NS1.
Premature termination codon (TGA) codons are underlined. CDNA, complementary DNA; MW, molecular weight; NS, Netherton syndrome.
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DISCUSSION
Netherton syndrome is caused by SPINK5 mutations, for
which, to date, at least 60 different loss-of-function mutations
have been reported (http://www.hgmd.cf.ac.uk). Among
these, almost 29% alter SPINK5 transcript splicing by
disrupting consensus acceptor or donor splice sites. Here,
we describe new unusual SPINK5 causative mutations, which
could have been misdiagnosed as silent polymorphisms
because of their nature and/or position. We also show
evidence for inter- and intra-familial variability in disease
expression despite negative LEKTI in the skin.
Clinical presentation differed from the classical congenital
scaly erythroderma in seven patients who showed no
exfoliative erythroderma at birth, but showed extensive
redness of the skin or eczematous-like plaques instead.
Eczematous-like plaques varied in size, aspect, and location,
but developed in all patients studied. Hair abnormalities also
showed a wide range of variations between patients and
during the course of the disease, with several patients having
a history of transitory hair loss in the neonatal period or
during infancy followed by slow hair re-growth. Two patients
(4.1 and 4.2) showed no detectable TI at the age of 5 years
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Figure 3. LEKTI expression in skin and cultured keratinocytes from NS patients 1 and 2. (a) Immunohistochemistry experiment performed on NS1, NS2,
and healthy control skin sections. Bar¼ 50 mm. (b) Western blotting of keratinocyte supernatant from NS1, NS2 (NSK1 and NSK2), healthy control (NHK), and
a Netherton syndrome (NS) patient with a homozygous SPINK5-null mutation (NSK), using LEKTI antibodies raised against D1–D6 and D13–D15 domains.
(c) In situ zymography analysis. Protease activity is represented by a pseudo-color gradient, which represents the intensity values of fluorescence. The values
of signal range from 0 (dark) to 255 (white). The dotted line represents the basal membrane of the epidermis. Bar¼ 50 mm. (d) Quantitative RT-PCR analysis
on cultured primary keratinocytes from NS patients 1 (NSK1) and 2 (NSK2), three healthy individuals (NHK), and two NS patients with LEKTI-null expression
(NSK). *, Po0.05; **, Po0,01. The results are the mean of two independent experiments. HPRT, hypoxanthine-guanine phosphoribosyl transferase;
MW, molecular weight; TNF, tumor necrosis factor; TSLP, thymic stromal lymphopoietin.
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and 9 months, respectively, which delayed the diagnosis
of NS in the absence of typical skin manifestations. ILC, a
highly specific feature of NS, was seen in every patient except
two (4.1 and 8), but its clinical aspect was highly variable
between patients, ranging from minor and localized scaly
lesions to extensive, inflammatory, and ichthyotic plaques
(Figure 1). Pruritus was a constant, often disabling and
aggravating feature. The disease showed a fluctuating course,
adding considerable heterogeneity in patient clinical pre-
sentation.
We and others previously reported a correlation between
epidermal protease activity, LEKTI detection, and disease
severity in rare NS patients with residual LEKTI expression in
the skin (Descargues et al., 2006; Hachem et al., 2006). In
these unusual patients, reduced expression of LEKTI frag-
ments, retaining some functional activity, is thought to
attenuate disease severity. In this study, LEKTI immunostain-
ing was negative in all patients, although two NS patients
(NS1 and NS2) displayed residual LEKTI expression in
cultured keratinocytes. These patients carried the deep
intronic c.1820þ53G4A and c.283-12T4A mutations in
introns 19 and 4, which induced partial intron retention
due to the activation of cryptic splice sites. Transcript
analysis revealed that abnormally spliced forms containing
intron 19 or 4 sequences were less abundant than normally
spliced SPINK5 transcripts, suggesting that mutations
c.1820þ 53G4A and c.283-12T4A did not completely
abolish normal splicing and/or may lead to nonsense-
mediated mRNA decay. In fact, we showed that residual
LEKTI fragments secreted by NS1 and NS2 keratinocytes
retained some functional activity as shown by in situ zymo-
graphy and cytokine expression profiles. This is consistent
with these mutations being ‘‘leaky’’ mutations, allowing for
the production of some level of normal protein, which is not
sufficient to prevent the development of the disease. It is
possible that residual LEKTI may attenuate the phenotype in
patients NS1 and NS2, who did not show a severe form of NS.
However, additional genetic and/or environmental factors are
likely to affect disease expression, as shown by inter- and
intra-familial variations seen in the other families. Finally, the
clinical spectrum of NS appears to be much wider than
classically described, and atypical forms are likely to be
further diagnosed by LEKTI and SPINK5 testing.
All NS patients included in our study displayed the
c.891C4T sequence variation in exon 11 on one SPINK5
allele. This nucleotide change was translationally silent but
changed the balance between ESE and exonic splicing
silencer sequences, inducing out-of-frame skipping of exon
11 and a premature termination codon in exon 12. This
altered splicing mechanism is the first described splicing
mechanism in NS involving an ESE sequence. The mutant
transcripts lacking exon 11 were expressed at a similar level
than the transcripts containing exon 11, suggesting that
mutation c.891C4T was fully penetrant. In fact, c.891C4T
is the most common SPINK5 mutation described so far in the
European population (10 out of 105 families (i.e., 9.5%) from
our international NS cohort). Although additional cases need
to be studied, our findings suggest that the high frequency of
this mutation may result from a founder effect in families
originating from Mediterranean countries.
Mutations c.1820þ53G4A and c.283-12T4A, together
with the previously described c.1431-12G4A mutation
(Raghunath et al., 2004), are the first SPINK5 mutations to
our knowledge to be located so distant from a consensus
splicing site. This may have delayed the recognition of this
sequence variation as being a disease-causing mutation before.
In conclusion, our results widen the clinical and molecular
spectrum of NS, revealing considerable clinical variations in
the disease phenotype, and open new diagnostic perspectives
to identify causative mutations in NS patients with unchar-
acterized SPINK5 allele.
MATERIALS AND METHODS
Patients and clinical material
Our study included 12 patients with a non-ambiguous diagnosis of
NS. The diagnosis was based on clinical criteria and was confirmed
by negative LEKTI immunostaining (Table 1). Written informed
consent was obtained from all NS patients (or parents) from whom
blood was collected. This work was approved by the Local Ethical
Committee (DEC 04005) and conducted according to the Declara-
tion of Helsinki Principles.
Primary keratinocyte culture and western blotting
Healthy human and NS primary keratinocytes were isolated
and cultured as previously described (Bitoun et al., 2003). Secreted
proteins of cultured keratinocytes were analyzed with LEKTI antibodies
raised against D1–D6 or D13–D15 domains (Deraison et al., 2007).
Reverse transcription-PCR analysis and complementary DNA
sequencing
RNA was extracted from keratinocytes, and first-strand complementary
DNA synthesis was carried out using superscript III reverse transcrip-
tase (Invitrogen, Carlsbad, CA; Briot et al., 2009). Primers used are
described in Supplementary Table S2 online. For c.283-12T4A, PCR
products were analyzed by capillary electrophoresis using FAM-
labeled primer. The complementary DNA amplimers were cloned into
PGEM-T vector and sequenced using the T7 and SP6 primers.
Genotype analysis
Polymorphic microsatellite markers D5S2033, D5S638, D5S2090,
D5S434, (CA)20 (AJ304417) and (GT)17 (AJ304416), and D5S413,
surrounding SPINK5 ATG, were used (Supplementary Table S2 online).
Prediction of pre-mRNA splicing sites and exonic splicing
sequences
Genomic environment of the mutation and exonic splicing
sequences were analyzed with Automated Splice Site Analysis
(https://splice.cmh.edu/; Nalla and Rogan, 2005), Human Splicing
Factor (http://www.umd.be/HSF/; Desmet et al., 2009), and ESE
Finder (http://rulai.cshl.edu/tools/ESE/; Cartegni et al., 2003).
Immunostaining and in situ zymography
Skin cross-sections were stained with LEKTI mAb, which recognizes
fragment D1–D6, as previously described (Bitoun et al., 2003).
In situ zymography was performed as reported earlier (Bonnart
et al., 2010).
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